vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and AXT INC (AXTI). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $26.9M, roughly 1.7× AXT INC). On growth, AXT INC posted the faster year-over-year revenue change (39.1% vs 7.0%). Over the past eight quarters, AXT INC's revenue compounded faster (-1.8% CAGR vs -18.3%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
AXT Inc designs, manufactures and sells high-performance compound semiconductor substrates, including gallium arsenide, indium phosphide and germanium wafers. Its products power optoelectronic and radio frequency devices for global communications, consumer electronics and industrial end markets.
AMRN vs AXTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $26.9M |
| Net Profit | $-10.5M | — |
| Gross Margin | — | 29.6% |
| Operating Margin | 35.5% | 64.5% |
| Net Margin | -23.3% | — |
| Revenue YoY | 7.0% | 39.1% |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $26.9M | ||
| Q4 25 | $49.2M | $23.0M | ||
| Q3 25 | $49.7M | $28.0M | ||
| Q2 25 | $72.7M | $18.0M | ||
| Q1 25 | $42.0M | $19.4M | ||
| Q4 24 | $62.3M | $25.1M | ||
| Q3 24 | $42.3M | $23.6M | ||
| Q2 24 | $67.5M | $27.9M |
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $-3.5M | ||
| Q3 25 | $-7.7M | $-1.9M | ||
| Q2 25 | $-14.1M | $-7.0M | ||
| Q1 25 | $-15.7M | $-8.8M | ||
| Q4 24 | $-48.6M | $-5.1M | ||
| Q3 24 | $-25.1M | $-2.9M | ||
| Q2 24 | $1.5M | $-1.5M |
| Q1 26 | — | 29.6% | ||
| Q4 25 | 47.1% | 20.9% | ||
| Q3 25 | 44.7% | 22.3% | ||
| Q2 25 | 69.2% | 8.0% | ||
| Q1 25 | 59.8% | -6.4% | ||
| Q4 24 | -15.4% | 17.6% | ||
| Q3 24 | 38.5% | 24.0% | ||
| Q2 24 | 63.4% | 27.4% |
| Q1 26 | 35.5% | 64.5% | ||
| Q4 25 | -12.9% | -16.6% | ||
| Q3 25 | -22.4% | -4.0% | ||
| Q2 25 | -22.0% | -37.5% | ||
| Q1 25 | -39.9% | -53.1% | ||
| Q4 24 | -84.3% | -24.6% | ||
| Q3 24 | -59.5% | -14.4% | ||
| Q2 24 | -0.8% | -6.8% |
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | -15.4% | ||
| Q3 25 | -15.6% | -6.8% | ||
| Q2 25 | -19.4% | -39.0% | ||
| Q1 25 | -37.4% | -45.5% | ||
| Q4 24 | -78.0% | -20.3% | ||
| Q3 24 | -59.4% | -12.4% | ||
| Q2 24 | 2.3% | -5.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $-0.09 | ||
| Q3 25 | $-0.02 | $-0.04 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $-0.04 | $-0.20 | ||
| Q4 24 | $-0.12 | $-0.11 | ||
| Q3 24 | $-0.06 | $-0.07 | ||
| Q2 24 | $0.00 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $107.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $298.4M |
| Total Assets | $645.8M | $444.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $107.1M | ||
| Q4 25 | $302.6M | $120.3M | ||
| Q3 25 | $286.6M | $23.1M | ||
| Q2 25 | $298.7M | $27.0M | ||
| Q1 25 | $281.8M | $31.6M | ||
| Q4 24 | $294.2M | $22.8M | ||
| Q3 24 | $305.7M | $24.9M | ||
| Q2 24 | $306.7M | $29.5M |
| Q1 26 | — | $298.4M | ||
| Q4 25 | $459.3M | $273.3M | ||
| Q3 25 | $458.9M | $179.1M | ||
| Q2 25 | $464.9M | $179.7M | ||
| Q1 25 | $473.7M | $185.0M | ||
| Q4 24 | $486.2M | $192.8M | ||
| Q3 24 | $531.4M | $200.7M | ||
| Q2 24 | $551.9M | $199.7M |
| Q1 26 | $645.8M | $444.6M | ||
| Q4 25 | $670.8M | $433.8M | ||
| Q3 25 | $659.8M | $334.0M | ||
| Q2 25 | $670.1M | $329.0M | ||
| Q1 25 | $655.7M | $333.5M | ||
| Q4 24 | $685.3M | $339.3M | ||
| Q3 24 | $750.6M | $355.6M | ||
| Q2 24 | $799.9M | $349.4M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
AXTI
Segment breakdown not available.
